Victory Capital Management Inc Akebia Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$95.7 Billion
Q4 2024

A detailed history of Victory Capital Management Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 25,681 shares of AKBA stock, worth $47,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,681

Previous 25,345 1.33%

Holding current value

$47,509

Previous $33,000 42.42%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$1.26 - $2.13 $423 - $715	336 Added 1.33%	25,681 $47,000
Q3 2024 Nov 05, 2024	BUY	$0.94 - $1.55 $486 - $802	518 Added 2.09%	25,345 $33,000
Q2 2024 Aug 05, 2024	BUY	$0.86 - $1.63 $2,588 - $4,906	3,010 Added 13.8%	24,827 $25,000
Q1 2024 May 03, 2024	SELL	$1.27 - $2.24 $891 - $1,572	-702 Reduced 3.12%	21,817 $39,000
Q4 2023 Feb 05, 2024	SELL	$0.8 - $1.28 $586,375 - $938,200	-732,969 Reduced 97.02%	22,519 $27,000
Q3 2023 Nov 06, 2023	BUY	$0.87 - $1.84 $81,423 - $172,205	93,590 Added 14.14%	755,488 $861,000
Q2 2023 Jul 27, 2023	BUY	$0.51 - $1.43 $206,118 - $577,940	404,154 Added 156.8%	661,898 $608,000
Q1 2023 May 02, 2023	BUY	$0.56 - $1.15 $133,236 - $273,610	237,922 Added 1200.29%	257,744 $144,000
Q4 2022 Feb 09, 2023	SELL	$0.25 - $0.58 $2 - $4	-8 Reduced 0.04%	19,822 $11,000
Q3 2022 Nov 02, 2022	SELL	$0.3 - $0.46 $1,244 - $1,908	-4,148 Reduced 17.3%	19,830 $6,000
Q2 2022 Aug 01, 2022	BUY	$0.32 - $0.67 $308 - $646	965 Added 4.19%	23,978 $8,000
Q1 2022 May 04, 2022	SELL	$0.72 - $2.93 $473 - $1,925	-657 Reduced 2.78%	23,013 $10,000
Q4 2021 Feb 07, 2022	SELL	$2.26 - $3.34 $1,530 - $2,261	-677 Reduced 2.78%	23,670 $53,000
Q3 2021 Nov 02, 2021	BUY	$2.35 - $3.88 $2,075 - $3,426	883 Added 3.76%	24,347 $70,000
Q2 2021 Aug 03, 2021	BUY	$2.83 - $4.2 $781 - $1,159	276 Added 1.19%	23,464 $89,000
Q1 2021 May 04, 2021	BUY	$2.92 - $5.06 $1,953 - $3,385	669 Added 2.97%	23,188 $78,000
Q4 2020 Feb 01, 2021	BUY	$2.22 - $3.78 $2,952 - $5,027	1,330 Added 6.28%	22,519 $63,000
Q3 2020 Nov 09, 2020	SELL	$2.39 - $13.08 $2,719 - $14,885	-1,138 Reduced 5.1%	21,189 $53,000
Q2 2020 Aug 07, 2020	BUY	$6.67 - $13.58 $22,484 - $45,778	3,371 Added 17.78%	22,327 $303,000
Q1 2020 May 04, 2020	SELL	$4.1 - $10.24 $45,735 - $114,227	-11,155 Reduced 37.05%	18,956 $144,000
Q4 2019 Feb 06, 2020	BUY	$3.16 - $6.73 $33,878 - $72,152	10,721 Added 55.29%	30,111 $190,000
Q4 2019 Feb 04, 2020	SELL	$3.16 - $6.73 $1,763 - $3,755	-558 Reduced 2.8%	19,390 $140,000
Q3 2019 Nov 12, 2019	BUY	$3.55 - $5.4 $70,815 - $107,719	19,948 New	19,948 $78,000

Others Institutions Holding AKBA

# of Institutions

128

Shares Held

63.3M

Call Options Held

50.6K

Put Options Held

203K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $340M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Akebia Therapeutics, Inc. Transaction History